File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

TitleRemdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Authors
Choy, KTWong, AYLKaewpreedee, PSia, SFChen, DHui, KPYChu, DKWChan, MCWCheung, PPHHuang, XPeiris, MYen, HL
KeywordsCOVID-19
Remdesivir
Lopinavir
Ritonavir
Emetine
Issue Date2020
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/antiviral
Citation
Antiviral Research, 2020, v. 178, p. article no. 104786 How to Cite?
DOI: http://dx.doi.org/10.1016/j.antiviral.2020.104786
AbstractAn escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 muM, 26.63 muM, 2.55 muM and 0.46 muM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 muM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 muM in combination with emetine at 0.195 muM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.
Persistent Identifierhttp://hdl.handle.net/10722/285254
ISSN
0166-3542
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.500
ISI Accession Number ID
WOS:000540343900008

 

DC FieldValueLanguage
dc.contributor.authorChoy, KT-
dc.contributor.authorWong, AYL-
dc.contributor.authorKaewpreedee, P-
dc.contributor.authorSia, SF-
dc.contributor.authorChen, D-
dc.contributor.authorHui, KPY-
dc.contributor.authorChu, DKW-
dc.contributor.authorChan, MCW-
dc.contributor.authorCheung, PPH-
dc.contributor.authorHuang, X-
dc.contributor.authorPeiris, M-
dc.contributor.authorYen, HL-
dc.date.accessioned2020-08-18T03:51:43Z-
dc.date.available2020-08-18T03:51:43Z-
dc.date.issued2020-
dc.identifier.citationAntiviral Research, 2020, v. 178, p. article no. 104786-
dc.identifier.issn0166-3542-
dc.identifier.urihttp://hdl.handle.net/10722/285254-
dc.description.abstractAn escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 muM, 26.63 muM, 2.55 muM and 0.46 muM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 muM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 muM in combination with emetine at 0.195 muM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/antiviral-
dc.relation.ispartofAntiviral Research-
dc.subjectCOVID-19-
dc.subjectRemdesivir-
dc.subjectLopinavir-
dc.subjectRitonavir-
dc.subjectEmetine-
dc.titleRemdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro-
dc.typeArticle-
dc.identifier.emailChoy, KT: ktchoy@hku.hk-
dc.identifier.emailWong, AYL: awong18@hku.hk-
dc.identifier.emailKaewpreedee, P: kpra@hku.hk-
dc.identifier.emailSia, SF: sfsia@hku.hk-
dc.identifier.emailHui, KPY: kenrie@hku.hk-
dc.identifier.emailChu, DKW: dkwchu@hku.hk-
dc.identifier.emailChan, MCW: mchan@hku.hk-
dc.identifier.emailPeiris, M: malik@hkucc.hku.hk-
dc.identifier.emailYen, HL: hyen@hku.hk-
dc.identifier.authorityHui, KPY=rp02149-
dc.identifier.authorityChu, DKW=rp02512-
dc.identifier.authorityChan, MCW=rp00420-
dc.identifier.authorityPeiris, M=rp00410-
dc.identifier.authorityYen, HL=rp00304-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.antiviral.2020.104786-
dc.identifier.pmid32251767-
dc.identifier.scopuseid_2-s2.0-85083015280-
dc.identifier.hkuros313032-
dc.identifier.volume178-
dc.identifier.spagearticle no. 104786-
dc.identifier.epagearticle no. 104786-
dc.identifier.isiWOS:000540343900008-
dc.publisher.placeNetherlands-
dc.identifier.issnl0166-3542-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats